Semaglutide roughly doubles the weight loss percentage of phentermine (13.7% versus 5-10%) over a much longer treatment duration
Available under brand names including Wegovy (FDA-approved for weight loss) and Ozempic (FDA-approved for diabetes, not for weight loss), semaglutide mimics the action of naturally occurring GLP-1, a hormone released by the intestine in response to food intake
While these therapeutic benefits are significant, they come with specific safety measures to ensure proper use
The table shows that resmetirom is a small (molecular weight about 600 g/mol), non-iodinated THR- agonist administered once daily as an oral tablet, while semaglutide is a large (about 4 kDa) GLP-1 peptide designed for once-weekly subcutaneous injection or, with SNAC enhancement, once-daily oral administration
Common management strategies for constipation include: Increasing water consumption